AVBP
ArriVent BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.49
+3.61%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -13.9%
- EBIT
- -18.6%
- EPS
- +8.5%
- Free cash flow
- -16.8%
- Operating cash flow
- -16.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +5.1%
- EPS
- -10.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -88.2%
- Net income
- —
- EPS
- -68.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026